Download PDFPDF
Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Estrogen receptor beta immunohistochemistry: time to get it right
    • Valerie Speirs, Senior lecturer
    • Other Contributors:
      • Caroline A. Green, and Abeer M. Shaaban

    Dear Editor

    We read with interest the paper by Borgquist et al (2008), published recently in Journal of Clinical Pathology1. In their article the authors aimed to investigate the impact of ERbeta expression on breast cancer outcome using a cohort of 512 tumours represented in tissue microarray (TMA). Since the discovery of ERbeta over a decade ago, this has been the goal of many research groups. However pr...

    Show More
    Conflict of Interest:
    None declared.